Loading...

Adam Boxer, MD, PhD

TitleProfessor
SchoolUCSF School of Medicine
DepartmentNeurology
Address675 Nelson Rising Lane
San Francisco CA 94158
Phone415-476-0668
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    New York UniversityM.D.1998School of Medicine

    Collapse Research 
    Collapse Research Activities and Funding
    The Frontotemporal Lobar Degeneration Clinical Research Consortium
    NIH/NINDS U54NS092089Sep 30, 2014 - Jul 31, 2019
    Role: Principal Investigator
    The Four Repeat Tauopathy Neuroimaging Initiative
    NIH/NIA R01AG038791Sep 30, 2010 - Feb 28, 2021
    Role: Principal Investigator
    Eye Movement Control in Normal Elderly and MCI
    NIH/NIA R01AG031278Apr 1, 2009 - Mar 31, 2014
    Role: Principal Investigator
    Ocular motor function and decision-making in FTLD
    NIH/NINDS K23NS048855Apr 6, 2005 - Mar 30, 2010
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites
    Collapse In The News
    Collapse Clinical Trials
    Collapse Global Health
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Perry DC, Brown JA, Possin KL, Datta S, Trujillo A, Radke A, Karydas A, Kornak J, Sias AC, Rabinovici GD, Gorno-Tempini ML, Boxer A, De May M, Rankin KP, Sturm VE, Lee SE, Matthews BR, Kao AW, Vossel KA, Tartaglia MC, Miller ZA, Seo SW, Sidhu M, Gaus SE, Nana AL, Vargas JNS, Hwang JL, Ossenkoppele R, Brown AB, Huang EJ, Coppola G, Rosen HJ, Geschwind D, Trojanowski JQ, Grinberg LT, Kramer JH, Miller BL, Seeley WW. Clinicopathological correlations in behavioural variant frontotemporal dementia. Brain. 2017 Dec 01; 140(12):3329-3345. PMID: 29053860.
      View in: PubMed
    2. Schonhaut DR, McMillan CT, Spina S, Dickerson BC, Siderowf A, Devous MD, Tsai R, Winer J, Russell DS, Litvan I, Roberson ED, Seeley WW, Grinberg LT, Kramer JH, Miller BL, Pressman P, Nasrallah I, Baker SL, Gomperts SN, Johnson KA, Grossman M, Jagust WJ, Boxer A, Rabinovici GD. (18) F-flortaucipir tau PET distinguishes established progressive supranuclear palsy from controls and Parkinson's disease: A multicenter study. Ann Neurol. 2017 Oct 05. PMID: 28980714.
      View in: PubMed
    3. Walsh CM, Ruoff L, Walker K, Emery A, Varbel J, Karageorgiou E, Luong PN, Mance I, Heuer HW, Boxer A, Grinberg LT, Kramer JH, Miller BL, Neylan TC. Sleepless night and day, the plight of Progressive Supranuclear Palsy. Sleep. 2017 Oct 05. PMID: 29029214.
      View in: PubMed
    4. Ranasinghe KG, Hinkley LB, Beagle AJ, Mizuiri D, Honma SM, Welch AE, Hubbard I, Mandelli ML, Miller ZA, Garrett C, La A, Boxer A, Houde JF, Miller BL, Vossel KA, Gorno-Tempini ML, Nagarajan SS. Distinct spatiotemporal patterns of neuronal functional connectivity in primary progressive aphasia variants. Brain. 2017 Oct 01; 140(10):2737-2751. PMID: 28969381.
      View in: PubMed
    5. Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, Tsai RM, Spina S, Grinberg LT, Rojas JC, Gallardo G, Wang K, Roh J, Robinson G, Finn MB, Jiang H, Sullivan PM, Baufeld C, Wood MW, Sutphen C, McCue L, Xiong C, Del-Aguila JL, Morris JC, Cruchaga C, Fagan AM, Miller BL, Boxer A, Seeley WW, Butovsky O, Barres BA, Paul SM, Holtzman DM. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017 Sep 28; 549(7673):523-527. PMID: 28959956.
      View in: PubMed
    6. Elahi FM, Marx G, Cobigo Y, Staffaroni AM, Kornak J, Tosun D, Boxer A, Kramer JH, Miller BL, Rosen HJ. Longitudinal white matter change in frontotemporal dementia subtypes and sporadic late onset Alzheimer's disease. Neuroimage Clin. 2017; 16:595-603. PMID: 28975068.
      View in: PubMed
    7. Brown JA, Hua AY, Trujllo A, Attygalle S, Binney RJ, Spina S, Lee SE, Kramer JH, Miller BL, Rosen HJ, Boxer A, Seeley WW. Advancing functional dysconnectivity and atrophy in progressive supranuclear palsy. Neuroimage Clin. 2017; 16:564-574. PMID: 28951832.
      View in: PubMed
    8. Boxer A, Yu JT, Golbe LI, Litvan I, Lang AE, Höglinger GU. Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol. 2017 Jul; 16(7):552-563. PMID: 28653647.
      View in: PubMed
    9. Whitwell JL, Höglinger GU, Antonini A, Bordelon Y, Boxer A, Colosimo C, van Eimeren T, Golbe LI, Kassubek J, Kurz C, Litvan I, Pantelyat A, Rabinovici G, Respondek G, Rominger A, Rowe JB, Stamelou M, Josephs KA. Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be? Mov Disord. 2017 Jul; 32(7):955-971. PMID: 28500751.
      View in: PubMed
    10. Fernández-Fournier M, Perry DC, Tartaglia MC, de May M, Boxer A, Coppola G, Christine CW, Huang EJ, Seeley WW, Miller BL, DeArmond SJ, Grinberg LT, Geschwind MD. Precipitous Deterioration of Motor Function, Cognition, and Behavior. JAMA Neurol. 2017 May 01; 74(5):591-596. PMID: 28264087.
      View in: PubMed
    11. Höglinger GU, Schöpe J, Stamelou M, Kassubek J, Del Ser T, Boxer A, Wagenpfeil S, Huppertz HJ. Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials. Mov Disord. 2017 Jun; 32(6):842-852. PMID: 28436538.
      View in: PubMed
    12. Yanamandra K, Patel TK, Jiang H, Schindler S, Ulrich JD, Boxer A, Miller BL, Kerwin DR, Gallardo G, Stewart F, Finn MB, Cairns NJ, Verghese PB, Fogelman I, West T, Braunstein J, Robinson G, Keyser J, Roh J, Knapik SS, Hu Y, Holtzman DM. Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy. Sci Transl Med. 2017 Apr 19; 9(386). PMID: 28424326.
      View in: PubMed
    13. Gendron TF, Chew J, Stankowski JN, Hayes LR, Zhang YJ, Prudencio M, Carlomagno Y, Daughrity LM, Jansen-West K, Perkerson EA, O'Raw A, Cook C, Pregent L, Belzil V, van Blitterswijk M, Tabassian LJ, Lee CW, Yue M, Tong J, Song Y, Castanedes-Casey M, Rousseau L, Phillips V, Dickson DW, Rademakers R, Fryer JD, Rush BK, Pedraza O, Caputo AM, Desaro P, Palmucci C, Robertson A, Heckman MG, Diehl NN, Wiggs E, Tierney M, Braun L, Farren J, Lacomis D, Ladha S, Fournier CN, McCluskey LF, Elman LB, Toledo JB, McBride JD, Tiloca C, Morelli C, Poletti B, Solca F, Prelle A, Wuu J, Jockel-Balsarotti J, Rigo F, Ambrose C, Datta A, Yang W, Raitcheva D, Antognetti G, McCampbell A, Van Swieten JC, Miller BL, Boxer A, Brown RH, Bowser R, Miller TM, Trojanowski JQ, Grossman M, Berry JD, Hu WT, Ratti A, Traynor BJ, Disney MD, Benatar M, Silani V, Glass JD, Floeter MK, Rothstein JD, Boylan KB, Petrucelli L. Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. Sci Transl Med. 2017 Mar 29; 9(383). PMID: 28356511.
      View in: PubMed
    14. Binney RJ, Pankov A, Marx G, He X, McKenna F, Staffaroni AM, Kornak J, Attygalle S, Boxer A, Schuff N, Gorno-Tempini ML, Weiner MW, Kramer JH, Miller BL, Rosen HJ. Data-driven regions of interest for longitudinal change in three variants of frontotemporal lobar degeneration. Brain Behav. 2017 Apr; 7(4):e00675. PMID: 28413716.
      View in: PubMed
    15. Yokoyama JS, Karch CM, Fan CC, Bonham LW, Kouri N, Ross OA, Rademakers R, Kim J, Wang Y, Höglinger GU, Müller U, Ferrari R, Hardy J, Momeni P, Sugrue LP, Hess CP, James Barkovich A, Boxer A, Seeley WW, Rabinovici GD, Rosen HJ, Miller BL, Schmansky NJ, Fischl B, Hyman BT, Dickson DW, Schellenberg GD, Andreassen OA, Dale AM, Desikan RS. Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia. Acta Neuropathol. 2017 May; 133(5):825-837. PMID: 28271184.
      View in: PubMed
    16. Spina S, Schonhaut DR, Boeve BF, Seeley WW, Ossenkoppele R, O'Neil JP, Lazaris A, Rosen HJ, Boxer A, Perry DC, Miller BL, Dickson DW, Parisi JE, Jagust WJ, Murray ME, Rabinovici GD. Frontotemporal dementia with the V337M MAPT mutation: Tau-PET and pathology correlations. Neurology. 2017 Feb 21; 88(8):758-766. PMID: 28130473.
      View in: PubMed
    17. Chen J, Yu JT, Wojta K, Wang HF, Zetterberg H, Blennow K, Yokoyama JS, Weiner MW, Kramer JH, Rosen H, Miller BL, Coppola G, Boxer A. Genome-wide association study identifies MAPT locus influencing human plasma tau levels. Neurology. 2017 Feb 14; 88(7):669-676. PMID: 28100725.
      View in: PubMed
    18. Seo SW, Ayakta N, Grinberg LT, Villeneuve S, Lehmann M, Reed B, DeCarli C, Miller BL, Rosen HJ, Boxer A, O'Neil JP, Jin LW, Seeley WW, Jagust WJ, Rabinovici GD. Regional correlations between [11C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort. Neuroimage Clin. 2017; 13:130-137. PMID: 27981028.
      View in: PubMed
    19. Miller ZA, Sturm VE, Camsari GB, Karydas A, Yokoyama JS, Grinberg LT, Boxer A, Rosen HJ, Rankin KP, Gorno-Tempini ML, Coppola G, Geschwind DH, Rademakers R, Seeley WW, Graff-Radford NR, Miller BL. Increased prevalence of autoimmune disease within C9 and FTD/MND cohorts: Completing the picture. Neurol Neuroimmunol Neuroinflamm. 2016 Dec; 3(6):e301. PMID: 27844039.
      View in: PubMed
    20. Dutt S, Binney RJ, Heuer HW, Luong P, Attygalle S, Bhatt P, Marx GA, Elofson J, Tartaglia MC, Litvan I, McGinnis SM, Dickerson BC, Kornak J, Waltzman D, Voltarelli L, Schuff N, Rabinovici GD, Kramer JH, Jack CR, Miller BL, Rosen HJ, Boxer A. Progression of brain atrophy in PSP and CBS over 6 months and 1 year. Neurology. 2016 Nov 08; 87(19):2016-2025. PMID: 27742814.
      View in: PubMed
    21. Hewer S, Varley S, Boxer A, Paul E, Williams DR. Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale. Mov Disord. 2016 Oct; 31(10):1574-1577. PMID: 27324431.
      View in: PubMed
    22. Goetzl EJ, Kapogiannis D, Schwartz JB, Lobach IV, Goetzl L, Abner EL, Jicha GA, Karydas AM, Boxer A, Miller BL, et al. Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer's disease. FASEB J. 2016 Dec; 30(12):4141-4148. PMID: 27601437.
      View in: PubMed
    23. Ranasinghe KG, Rankin KP, Pressman PS, Perry DC, Lobach IV, Seeley WW, Coppola G, Karydas AM, Grinberg LT, Shany-Ur T, Lee SE, Rabinovici GD, Rosen HJ, Gorno-Tempini ML, Boxer A, Miller ZA, Chiong W, DeMay M, Kramer JH, Possin KL, Sturm VE, Bettcher BM, Neylan M, Zackey DD, Nguyen LA, Ketelle R, Block N, Wu TQ, Dallich A, Russek N, Caplan A, Geschwind DH, Vossel KA, Miller BL, et al. Distinct Subtypes of Behavioral Variant Frontotemporal Dementia Based on Patterns of Network Degeneration. JAMA Neurol. 2016 Sep 01; 73(9):1078-88. PMID: 27429218; PMCID: PMC5024785.
    24. Walsh CM, Ruoff L, Varbel J, Walker K, Grinberg LT, Boxer A, Kramer JH, Miller BL, Neylan TC. Rest-activity rhythm disruption in progressive supranuclear palsy. Sleep Med. 2016 Jun; 22:50-56. PMID: 27544836; PMCID: PMC4996365 [Available on 06/21/17].
    25. Zhang Y, Walter R, Ng P, Luong PN, Dutt S, Heuer H, Rojas-Rodriguez JC, Tsai R, Litvan I, Dickerson BC, Tartaglia MC, Rabinovici G, Miller BL, Rosen HJ, Schuff N, Boxer A. Progression of Microstructural Degeneration in Progressive Supranuclear Palsy and Corticobasal Syndrome: A Longitudinal Diffusion Tensor Imaging Study. PLoS One. 2016; 11(6):e0157218. PMID: 27310132; PMCID: PMC4911077.
    26. Tsai RM, Boxer A. Therapy and clinical trials in frontotemporal dementia: past, present, and future. J Neurochem. 2016 Aug; 138 Suppl 1:211-21. PMID: 27306957.
      View in: PubMed
    27. Santos-Santos MA, Mandelli ML, Binney RJ, Ogar J, Wilson SM, Henry ML, Hubbard HI, Meese M, Attygalle S, Rosenberg L, Pakvasa M, Trojanowski JQ, Grinberg LT, Rosen H, Boxer A, Miller BL, Seeley WW, Gorno-Tempini ML. Features of Patients With Nonfluent/Agrammatic Primary Progressive Aphasia With Underlying Progressive Supranuclear Palsy Pathology or Corticobasal Degeneration. JAMA Neurol. 2016 Jun 01; 73(6):733-42. PMID: 27111692; PMCID: PMC4924620 [Available on 06/01/17].
    28. Jaeger PA, Lucin KM, Britschgi M, Vardarajan B, Huang RP, Kirby ED, Abbey R, Boeve BF, Boxer A, Farrer LA, Finch N, Graff-Radford NR, Head E, Hofree M, Huang R, Johns H, Karydas A, Knopman DS, Loboda A, Masliah E, Narasimhan R, Petersen RC, Podtelezhnikov A, Pradhan S, Rademakers R, Sun CH, Younkin SG, Miller BL, Ideker T, Wyss-Coray T. Erratum to: Network-driven plasma proteomics expose molecular changes in the Alzheimer's brain. Mol Neurodegener. 2016 May 23; 11(1):42. PMID: 27216421.
      View in: PubMed
    29. Jaeger PA, Lucin KM, Britschgi M, Vardarajan B, Huang RP, Kirby ED, Abbey R, Boeve BF, Boxer A, Farrer LA, Finch N, Graff-Radford NR, Head E, Hoffree M, Huang R, Johns H, Karydas A, Knopman DS, Loboda A, Masliah E, Narasimhan R, Petersen RC, Podtelezhnikov A, Pradhan S, Rademakers R, Sun CH, Younkin SG, Miller BL, Ideker T, Wyss-Coray T. Network-driven plasma proteomics expose molecular changes in the Alzheimer's brain. Mol Neurodegener. 2016 Apr 26; 11:31. PMID: 27112350; PMCID: PMC4845325.
    30. Tsai RM, Lobach I, Bang J, Whitwell JL, Senjem ML, Jack CR, Rosen H, Miller B, Boxer A. Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy. Parkinsonism Relat Disord. 2016 Jul; 28:29-35. PMID: 27132501; PMCID: PMC4914401 [Available on 07/01/17].
    31. Bang J, Lobach IV, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, Doody RS, Lees A, Gold M, Morimoto BH, Boxer A. Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. Parkinsonism Relat Disord. 2016 Jul; 28:41-48. PMID: 27172829; PMCID: PMC4914418 [Available on 07/01/17].
    32. Stamelou M, Schöpe J, Wagenpfeil S, Del Ser T, Bang J, Lobach IY, Luong P, Respondek G, Oertel WH, Boxer A, Höglinger GU. Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy. Mov Disord. 2016 May; 31(5):742-7. PMID: 26948290.
      View in: PubMed
    33. Rojas JC, Karydas A, Bang J, Tsai RM, Blennow K, Liman V, Kramer JH, Rosen H, Miller BL, Zetterberg H, Boxer A. Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Clin Transl Neurol. 2016 Mar; 3(3):216-25. PMID: 27042681; PMCID: PMC4774256.
    34. Ranasinghe KG, Rankin KP, Lobach IV, Kramer JH, Sturm VE, Bettcher BM, Possin K, Christine You S, Lamarre AK, Shany-Ur T, Stephens ML, Perry DC, Lee SE, Miller ZA, Gorno-Tempini ML, Rosen HJ, Boxer A, Seeley WW, Rabinovici GD, Vossel KA, Miller BL. Cognition and neuropsychiatry in behavioral variant frontotemporal dementia by disease stage. Neurology. 2016 Feb 16; 86(7):600-10. PMID: 26802093; PMCID: PMC4762418 [Available on 02/16/17].
    35. Rojas JC, Boxer A. Neurodegenerative disease in 2015: Targeting tauopathies for therapeutic translation. Nat Rev Neurol. 2016 Feb; 12(2):74-6. PMID: 26794651.
      View in: PubMed
    36. Fredericks CA, Koestler M, Seeley W, Miller B, Boxer A, Grinberg LT. Primary chronic traumatic encephalopathy in an older patient with late-onset AD phenotype. Neurol Clin Pract. 2015 Dec; 5(6):475-479. PMID: 26716062.
      View in: PubMed
    37. Marlow CA, Viskontas IV, Matlin A, Boydston C, Boxer A, Taylor RP. Temporal Structure of Human Gaze Dynamics Is Invariant During Free Viewing. PLoS One. 2015; 10(9):e0139379. PMID: 26421613; PMCID: PMC4589360.
    38. Goetzl EJ, Boxer A, Schwartz JB, Abner EL, Petersen RC, Miller BL, Kapogiannis D. Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease. Neurology. 2015 Jul 07; 85(1):40-7. PMID: 26062630; PMCID: PMC4501943.
    39. Goetzl EJ, Boxer A, Schwartz JB, Abner EL, Petersen RC, Miller BL, Carlson OD, Mustapic M, Kapogiannis D. Low neural exosomal levels of cellular survival factors in Alzheimer's disease. Ann Clin Transl Neurol. 2015 Jul; 2(7):769-73. PMID: 26273689; PMCID: PMC4531059.
    40. Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, Madison C, Ayakta N, Ghosh PM, La Joie R, Arthur-Bentil SK, Vogel JW, Marks SM, Lehmann M, Rosen HJ, Reed B, Olichney J, Boxer A, Miller BL, Borys E, Jin LW, Huang EJ, Grinberg LT, DeCarli C, Seeley WW, Jagust W. Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain. 2015 Jul; 138(Pt 7):2020-33. PMID: 25953778; PMCID: PMC4806716.
    41. Sha SJ, Ghosh PM, Lee SE, Corbetta-Rastelli C, Jagust WJ, Kornak J, Rankin KP, Grinberg LT, Vinters HV, Mendez MF, Dickson DW, Seeley WW, Gorno-Tempini M, Kramer J, Miller BL, Boxer A, Rabinovici GD. Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. Alzheimers Res Ther. 2015; 7(1):8. PMID: 25733984; PMCID: PMC4346122.
    42. Finger EC, MacKinley J, Blair M, Oliver LD, Jesso S, Tartaglia MC, Borrie M, Wells J, Dziobek I, Pasternak S, Mitchell DG, Rankin K, Kertesz A, Boxer A. Oxytocin for frontotemporal dementia: a randomized dose-finding study of safety and tolerability. Neurology. 2015 Jan 13; 84(2):174-81. PMID: 25503617; PMCID: PMC4336088.
    43. Tsai RM, Boxer A. Treatment of frontotemporal dementia. Curr Treat Options Neurol. 2014 Nov; 16(11):319. PMID: 25238733; PMCID: PMC4920050.
    44. Lee SE, Khazenzon AM, Trujillo AJ, Guo CC, Yokoyama JS, Sha SJ, Takada LT, Karydas AM, Block NR, Coppola G, Pribadi M, Geschwind DH, Rademakers R, Fong JC, Weiner MW, Boxer A, Kramer JH, Rosen HJ, Miller BL, Seeley WW. Altered network connectivity in frontotemporal dementia with C9orf72 hexanucleotide repeat expansion. Brain. 2014 Nov; 137(Pt 11):3047-60. PMID: 25273996; PMCID: PMC4208465.
    45. Albers MW, Gilmore GC, Kaye J, Murphy C, Wingfield A, Bennett DA, Boxer A, Buchman AS, Cruickshanks KJ, Devanand DP, Duffy CJ, Gall CM, Gates GA, Granholm AC, Hensch T, Holtzer R, Hyman BT, Lin FR, McKee AC, Morris JC, Petersen RC, Silbert LC, Struble RG, Trojanowski JQ, Verghese J, Wilson DA, Xu S, Zhang LI. At the interface of sensory and motor dysfunctions and Alzheimer's disease. Alzheimers Dement. 2015 Jan; 11(1):70-98. PMID: 25022540; PMCID: PMC4287457.
    46. Tsai RM, Boxer A. Clinical trials: past, current, and future for atypical Parkinsonian syndromes. Semin Neurol. 2014 Apr; 34(2):225-34. PMID: 24963682; PMCID: PMC4920046.
    47. Wagshal D, Sankaranarayanan S, Guss V, Hall T, Berisha F, Lobach I, Karydas A, Voltarelli L, Scherling C, Heuer H, Tartaglia MC, Miller Z, Coppola G, Ahlijanian M, Soares H, Kramer JH, Rabinovici GD, Rosen HJ, Miller BL, Meredith J, Boxer A. Divergent CSF t alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 2015 Mar; 86(3):244-50. PMID: 24899730; PMCID: PMC4256124.
    48. Boxer A, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, Doody RS, Lees A, Golbe LI, Williams DR, Corvol JC, Ludolph A, Burn D, Lorenzl S, Litvan I, Roberson ED, Höglinger GU, Koestler M, Jack CR, Van Deerlin V, Randolph C, Lobach IV, Heuer HW, Gozes I, Parker L, Whitaker S, Hirman J, Stewart AJ, Gold M, Morimoto BH. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014 Jul; 13(7):676-85. PMID: 24873720; PMCID: PMC4129545.
    49. Tartaglia MC, Hu B, Mehta K, Neuhaus J, Yaffe K, Miller BL, Boxer A. Demographic and neuropsychiatric factors associated with off-label medication use in frontotemporal dementia and Alzheimer's disease. Alzheimer Dis Assoc Disord. 2014 Apr-Jun; 28(2):182-9. PMID: 23995817; PMCID: PMC3938980.
    50. Pa J, Dutt S, Mirsky JB, Heuer HW, Keselman P, Kong E, Trujillo A, Gazzaley A, Kramer JH, Seeley WW, Miller BL, Boxer A. The functional oculomotor network and saccadic cognitive control in healthy elders. Neuroimage. 2014 Jul 15; 95:61-8. PMID: 24675647; PMCID: PMC4043928.
    51. Li Y, Chen JA, Sears RL, Gao F, Klein ED, Karydas A, Geschwind MD, Rosen HJ, Boxer A, Guo W, Pellegrini M, Horvath S, Miller BL, Geschwind DH, Coppola G. An epigenetic signature in peripheral blood associated with the haplotype on 17q21.31, a risk factor for neurodegenerative tauopathy. PLoS Genet. 2014 Mar; 10(3):e1004211. PMID: 24603599; PMCID: PMC3945475.
    52. Scherling CS, Hall T, Berisha F, Klepac K, Karydas A, Coppola G, Kramer JH, Rabinovici G, Ahlijanian M, Miller BL, Seeley W, Grinberg LT, Rosen H, Meredith J, Boxer A. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol. 2014 Jan; 75(1):116-26. PMID: 24242746; PMCID: PMC4020786.
    53. Sánchez-Juan P, Ghosh PM, Hagen J, Gesierich B, Henry M, Grinberg LT, O'Neil JP, Janabi M, Huang EJ, Trojanowski JQ, Vinters HV, Gorno-Tempini M, Seeley WW, Boxer A, Rosen HJ, Kramer JH, Miller BL, Jagust WJ, Rabinovici GD. Practical utility of amyloid and FDG-PET in an academic dementia center. Neurology. 2014 Jan 21; 82(3):230-8. PMID: 24353340; PMCID: PMC3902757.
    54. Kramer JH, Mungas D, Possin KL, Rankin KP, Boxer A, Rosen HJ, Bostrom A, Sinha L, Berhel A, Widmeyer M. NIH EXAMINER: conceptualization and development of an executive function battery. J Int Neuropsychol Soc. 2014 Jan; 20(1):11-9. PMID: 24103232; PMCID: PMC4474183.
    55. Lee SE, Tartaglia MC, Yener G, Genç S, Seeley WW, Sanchez-Juan P, Moreno F, Mendez MF, Klein E, Rademakers R, López de Munain A, Combarros O, Kramer JH, Kenet RO, Boxer A, Geschwind MD, Gorno-Tempini ML, Karydas AM, Rabinovici GD, Coppola G, Geschwind DH, Miller BL. Neurodegenerative disease phenotypes in carriers of MAPT p.A152T, a risk factor for frontotemporal dementia spectrum disorders and Alzheimer disease. Alzheimer Dis Assoc Disord. 2013 Oct-Dec; 27(4):302-9. PMID: 23518664; PMCID: PMC3796183.
    56. Fong H, Wang C, Knoferle J, Walker D, Balestra ME, Tong LM, Leung L, Ring KL, Seeley WW, Karydas A, Kshirsagar MA, Boxer A, Kosik KS, Miller BL, Huang Y. Genetic correction of tauopathy phenotypes in neurons derived from human induced pluripotent stem cells. Stem Cell Reports. 2013; 1(3):226-34. PMID: 24319659; PMCID: PMC3849235.
    57. Heuer HW, Mirsky JB, Kong EL, Dickerson BC, Miller BL, Kramer JH, Boxer A. Antisaccade task reflects cortical involvement in mild cognitive impairment. Neurology. 2013 Oct 01; 81(14):1235-43. PMID: 23986300; PMCID: PMC3795604.
    58. Almeida S, Gascon E, Tran H, Chou HJ, Gendron TF, Degroot S, Tapper AR, Sellier C, Charlet-Berguerand N, Karydas A, Seeley WW, Boxer A, Petrucelli L, Miller BL, Gao FB. Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons. Acta Neuropathol. 2013 Sep; 126(3):385-99. PMID: 23836290; PMCID: PMC3753484.
    59. Possin KL, Feigenbaum D, Rankin KP, Smith GE, Boxer A, Wood K, Hanna SM, Miller BL, Kramer JH. Dissociable executive functions in behavioral variant frontotemporal and Alzheimer dementias. Neurology. 2013 Jun 11; 80(24):2180-5. PMID: 23658382; PMCID: PMC3721104.
    60. Miller ZA, Rankin KP, Graff-Radford NR, Takada LT, Sturm VE, Cleveland CM, Criswell LA, Jaeger PA, Stan T, Heggeli KA, Hsu SC, Karydas A, Khan BK, Grinberg LT, Gorno-Tempini ML, Boxer A, Rosen HJ, Kramer JH, Coppola G, Geschwind DH, Rademakers R, Seeley WW, Wyss-Coray T, Miller BL. TDP-43 frontotemporal lobar degeneration and autoimmune disease. J Neurol Neurosurg Psychiatry. 2013 Sep; 84(9):956-62. PMID: 23543794; PMCID: PMC3840954.
    61. Gardner RC, Boxer A, Trujillo A, Mirsky JB, Guo CC, Gennatas ED, Heuer HW, Fine E, Zhou J, Kramer JH, Miller BL, Seeley WW. Intrinsic connectivity network disruption in progressive supranuclear palsy. Ann Neurol. 2013 May; 73(5):603-16. PMID: 23536287; PMCID: PMC3732833.
    62. Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, Boxer A, Dickson DW, Grossman M, Hallett M, Josephs KA, Kertesz A, Lee SE, Miller BL, Reich SG, Riley DE, Tolosa E, Tröster AI, Vidailhet M, Weiner WJ. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013 Jan 29; 80(5):496-503. PMID: 23359374; PMCID: PMC3590050.
    63. Boxer A, Knopman DS, Kaufer DI, Grossman M, Onyike C, Graf-Radford N, Mendez M, Kerwin D, Lerner A, Wu CK, Koestler M, Shapira J, Sullivan K, Klepac K, Lipowski K, Ullah J, Fields S, Kramer JH, Merrilees J, Neuhaus J, Mesulam MM, Miller BL. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2013 Feb; 12(2):149-56. PMID: 23290598; PMCID: PMC3756890.
    64. Halabi C, Halabi A, Dean DL, Wang PN, Boxer A, Trojanowski JQ, Dearmond SJ, Miller BL, Kramer JH, Seeley WW. Patterns of striatal degeneration in frontotemporal dementia. Alzheimer Dis Assoc Disord. 2013 Jan-Mar; 27(1):74-83. PMID: 22367382; PMCID: PMC3389579.
    65. Sha SJ, Boxer A. Treatment implications of C9ORF72. Alzheimers Res Ther. 2012; 4(6):46. PMID: 23186535; PMCID: PMC3580455.
    66. Boxer A, Gold M, Huey E, Hu WT, Rosen H, Kramer J, Gao FB, Burton EA, Chow T, Kao A, Leavitt BR, Lamb B, Grether M, Knopman D, Cairns NJ, Mackenzie IR, Mitic L, Roberson ED, Van Kammen D, Cantillon M, Zahs K, Jackson G, Salloway S, Morris J, Tong G, Feldman H, Fillit H, Dickinson S, Khachaturian ZS, Sutherland M, Abushakra S, Lewcock J, Farese R, Kenet RO, Laferla F, Perrin S, Whitaker S, Honig L, Mesulam MM, Boeve B, Grossman M, Miller BL, Cummings JL. The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). Alzheimers Dement. 2013 Mar; 9(2):189-98. PMID: 23062850; PMCID: PMC3562382.
    67. Boxer A, Gold M, Huey E, Gao FB, Burton EA, Chow T, Kao A, Leavitt BR, Lamb B, Grether M, Knopman D, Cairns NJ, Mackenzie IR, Mitic L, Roberson ED, Van Kammen D, Cantillon M, Zahs K, Salloway S, Morris J, Tong G, Feldman H, Fillit H, Dickinson S, Khachaturian Z, Sutherland M, Farese R, Miller BL, Cummings J. Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development. Alzheimers Dement. 2013 Mar; 9(2):176-88. PMID: 23043900; PMCID: PMC3542408.
    68. Sha SJ, Takada LT, Rankin KP, Yokoyama JS, Rutherford NJ, Fong JC, Khan B, Karydas A, Baker MC, DeJesus-Hernandez M, Pribadi M, Coppola G, Geschwind DH, Rademakers R, Lee SE, Seeley W, Miller BL, Boxer A. Frontotemporal dementia due to C9ORF72 mutations: clinical and imaging features. Neurology. 2012 Sep 04; 79(10):1002-11. PMID: 22875087; PMCID: PMC3430713.
    69. Gennatas ED, Cholfin JA, Zhou J, Crawford RK, Sasaki DA, Karydas A, Boxer A, Bonasera SJ, Rankin KP, Gorno-Tempini ML, Rosen HJ, Kramer JH, Weiner M, Miller BL, Seeley WW. COMT Val158Met genotype influences neurodegeneration within dopamine-innervated brain structures. Neurology. 2012 May 22; 78(21):1663-9. PMID: 22573634; PMCID: PMC3359506.
    70. Hellmuth J, Mirsky J, Heuer HW, Matlin A, Jafari A, Garbutt S, Widmeyer M, Berhel A, Sinha L, Miller BL, Kramer JH, Boxer A. Multicenter validation of a bedside antisaccade task as a measure of executive function. Neurology. 2012 Jun 05; 78(23):1824-31. PMID: 22573640; PMCID: PMC3369520.
    71. Coppola G, Chinnathambi S, Lee JJ, Dombroski BA, Baker MC, Soto-Ortolaza AI, Lee SE, Klein E, Huang AY, Sears R, Lane JR, Karydas AM, Kenet RO, Biernat J, Wang LS, Cotman CW, Decarli CS, Levey AI, Ringman JM, Mendez MF, Chui HC, Le Ber I, Brice A, Lupton MK, Preza E, Lovestone S, Powell J, Graff-Radford N, Petersen RC, Boeve BF, Lippa CF, Bigio EH, Mackenzie I, Finger E, Kertesz A, Caselli RJ, Gearing M, Juncos JL, Ghetti B, Spina S, Bordelon YM, Tourtellotte WW, Frosch MP, Vonsattel JP, Zarow C, Beach TG, Albin RL, Lieberman AP, Lee VM, Trojanowski JQ, Van Deerlin VM, Bird TD, Galasko DR, Masliah E, White CL, Troncoso JC, Hannequin D, Boxer A, Geschwind MD, Kumar S, Mandelkow EM, Wszolek ZK, Uitti RJ, Dickson DW, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Ross OA, Rademakers R, Schellenberg GD, Miller BL, Mandelkow E, Geschwind DH. Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum Mol Genet. 2012 Aug 01; 21(15):3500-12. PMID: 22556362; PMCID: PMC3392107.
    72. Khan BK, Yokoyama JS, Takada LT, Sha SJ, Rutherford NJ, Fong JC, Karydas AM, Wu T, Ketelle RS, Baker MC, Hernandez MD, Coppola G, Geschwind DH, Rademakers R, Lee SE, Rosen HJ, Rabinovici GD, Seeley WW, Rankin KP, Boxer A, Miller BL. Atypical, slowly progressive behavioural variant frontotemporal dementia associated with C9ORF72 hexanucleotide expansion. J Neurol Neurosurg Psychiatry. 2012 Apr; 83(4):358-64. PMID: 22399793; PMCID: PMC3388906.
    73. Boxer A, Garbutt S, Seeley WW, Jafari A, Heuer HW, Mirsky J, Hellmuth J, Trojanowski JQ, Huang E, DeArmond S, Neuhaus J, Miller BL. Saccade abnormalities in autopsy-confirmed frontotemporal lobar degeneration and Alzheimer disease. Arch Neurol. 2012 Apr; 69(4):509-17. PMID: 22491196; PMCID: PMC3423186.
    74. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer A, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, Kouri N, Wojtas A, Sengdy P, Hsiung GY, Karydas A, Seeley WW, Josephs KA, Coppola G, Geschwind DH, Wszolek ZK, Feldman H, Knopman DS, Petersen RC, Miller BL, Dickson DW, Boylan KB, Graff-Radford NR, Rademakers R. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011 Oct 20; 72(2):245-56. PMID: 21944778; PMCID: PMC3202986.
    75. Mok K, Traynor BJ, Schymick J, Tienari PJ, Laaksovirta H, Peuralinna T, Myllykangas L, Chiò A, Shatunov A, Boeve BF, Boxer A, DeJesus-Hernandez M, Mackenzie IR, Waite A, Williams N, Morris HR, Simón-Sánchez J, van Swieten JC, Heutink P, Restagno G, Mora G, Morrison KE, Shaw PJ, Rollinson PS, Al-Chalabi A, Rademakers R, Pickering-Brown S, Orrell RW, Nalls MA, Hardy J. Chromosome 9 ALS and FTD locus is probably derived from a single founder. Neurobiol Aging. 2012 Jan; 33(1):209.e3-8. PMID: 21925771; PMCID: PMC3312749.
    76. Rankin KP, Mayo MC, Seeley WW, Lee S, Rabinovici G, Gorno-Tempini ML, Boxer A, Weiner MW, Trojanowski JQ, DeArmond SJ, Miller BL. Behavioral variant frontotemporal dementia with corticobasal degeneration pathology: phenotypic comparison to bvFTD with Pick's disease. J Mol Neurosci. 2011 Nov; 45(3):594-608. PMID: 21881831; PMCID: PMC3208125.
    77. Lee SE, Rabinovici GD, Mayo MC, Wilson SM, Seeley WW, DeArmond SJ, Huang EJ, Trojanowski JQ, Growdon ME, Jang JY, Sidhu M, See TM, Karydas AM, Gorno-Tempini ML, Boxer A, Weiner MW, Geschwind MD, Rankin KP, Miller BL. Clinicopathological correlations in corticobasal degeneration. Ann Neurol. 2011 Aug; 70(2):327-40. PMID: 21823158; PMCID: PMC3154081.
    78. Mirsky JB, Heuer HW, Jafari A, Kramer JH, Schenk AK, Viskontas IV, Miller BL, Boxer A. Anti-saccade performance predicts executive function and brain structure in normal elders. Cogn Behav Neurol. 2011 Jun; 24(2):50-8. PMID: 21697711; PMCID: PMC3775477.
    79. Goldman JS, Rademakers R, Huey ED, Boxer A, Mayeux R, Miller BL, Boeve BF. An algorithm for genetic testing of frontotemporal lobar degeneration. Neurology. 2011 Feb 01; 76(5):475-83. PMID: 21282594; PMCID: PMC3034412.
    80. Viskontas IV, Boxer A, Fesenko J, Matlin A, Heuer HW, Mirsky J, Miller BL. Visual search patterns in semantic dementia show paradoxical facilitation of binding processes. Neuropsychologia. 2011 Feb; 49(3):468-78. PMID: 21215762; PMCID: PMC3046767.
    81. Johnson JK, Pa J, Boxer A, Kramer JH, Freeman K, Yaffe K. Baseline predictors of clinical progression among patients with dysexecutive mild cognitive impairment. Dement Geriatr Cogn Disord. 2010; 30(4):344-51. PMID: 20938178; PMCID: PMC2975734.
    82. Kerchner GA, Boxer A. Bapineuzumab. Expert Opin Biol Ther. 2010 Jul; 10(7):1121-30. PMID: 20497044; PMCID: PMC3000430.
    83. Sturm VE, McCarthy ME, Yun I, Madan A, Yuan JW, Holley SR, Ascher EA, Boxer A, Miller BL, Levenson RW. Mutual gaze in Alzheimer's disease, frontotemporal and semantic dementia couples. Soc Cogn Affect Neurosci. 2011 Jun; 6(3):359-67. PMID: 20587598; PMCID: PMC3110436.
    84. Boxer A, Mackenzie IR, Boeve BF, Baker M, Seeley WW, Crook R, Feldman H, Hsiung GY, Rutherford N, Laluz V, Whitwell J, Foti D, McDade E, Molano J, Karydas A, Wojtas A, Goldman J, Mirsky J, Sengdy P, Dearmond S, Miller BL, Rademakers R. Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family. J Neurol Neurosurg Psychiatry. 2011 Feb; 82(2):196-203. PMID: 20562461; PMCID: PMC3017222.
    85. Pa J, Possin KL, Wilson SM, Quitania LC, Kramer JH, Boxer A, Weiner MW, Johnson JK. Gray matter correlates of set-shifting among neurodegenerative disease, mild cognitive impairment, and healthy older adults. J Int Neuropsychol Soc. 2010 Jul; 16(4):640-50. PMID: 20374676; PMCID: PMC2891121.
    86. Ross L, Neuhaus J, Knopman D, Kramer J, Boeve B, Caselli RJ, Graff-Radford N, Mendez MF, Miller BL, Boxer A. Off-label medication use in frontotemporal dementia. Am J Alzheimers Dis Other Demen. 2010 Mar; 25(2):128-33. PMID: 20124256; PMCID: PMC2862544.
    87. Boxer A, Lipton AM, Womack K, Merrilees J, Neuhaus J, Pavlic D, Gandhi A, Red D, Martin-Cook K, Svetlik D, Miller BL. An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord. 2009 Jul-Sep; 23(3):211-7. PMID: 19812461; PMCID: PMC2760056.
    88. Pa J, Boxer A, Chao LL, Gazzaley A, Freeman K, Kramer J, Miller BL, Weiner MW, Neuhaus J, Johnson JK. Clinical-neuroimaging characteristics of dysexecutive mild cognitive impairment. Ann Neurol. 2009 Apr; 65(4):414-23. PMID: 19399879; PMCID: PMC2680500.
    89. Agosta F, Vossel KA, Miller BL, Migliaccio R, Bonasera SJ, Filippi M, Boxer A, Karydas A, Possin KL, Gorno-Tempini ML. Apolipoprotein E epsilon4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia. Proc Natl Acad Sci U S A. 2009 Feb 10; 106(6):2018-22. PMID: 19164761; PMCID: PMC2644156.
    90. Garbutt S, Matlin A, Hellmuth J, Schenk AK, Johnson JK, Rosen H, Dean D, Kramer J, Neuhaus J, Miller BL, Lisberger SG, Boxer A. Oculomotor function in frontotemporal lobar degeneration, related disorders and Alzheimer's disease. Brain. 2008 May; 131(Pt 5):1268-81. PMID: 18362099; PMCID: PMC2367697.
    91. Boxer A, Boeve BF. Frontotemporal dementia treatment: current symptomatic therapies and implications of recent genetic, biochemical, and neuroimaging studies. Alzheimer Dis Assoc Disord. 2007 Oct-Dec; 21(4):S79-87. PMID: 18090429.
      View in: PubMed
    92. Boxer A, Rabinovici GD, Kepe V, Goldman J, Furst AJ, Huang SC, Baker SL, O'neil JP, Chui H, Geschwind MD, Small GW, Barrio JR, Jagust W, Miller BL. Amyloid imaging in distinguishing atypical prion disease from Alzheimer disease. Neurology. 2007 Jul 17; 69(3):283-90. PMID: 17636066.
      View in: PubMed
    93. Cardenas VA, Boxer A, Chao LL, Gorno-Tempini ML, Miller BL, Weiner MW, Studholme C. Deformation-based morphometry reveals brain atrophy in frontotemporal dementia. Arch Neurol. 2007 Jun; 64(6):873-7. PMID: 17562936; PMCID: PMC2733361.
    94. Yoon G, Kramer J, Zanko A, Guzijan M, Lin S, Foster-Barber A, Boxer A. Speech and language delay are early manifestations of juvenile-onset Huntington disease. Neurology. 2006 Oct 10; 67(7):1265-7. PMID: 17030763.
      View in: PubMed
    95. Boxer A, Garbutt S, Rankin KP, Hellmuth J, Neuhaus J, Miller BL, Lisberger SG. Medial versus lateral frontal lobe contributions to voluntary saccade control as revealed by the study of patients with frontal lobe degeneration. J Neurosci. 2006 Jun 07; 26(23):6354-63. PMID: 16763044; PMCID: PMC2551317.
    96. Boxer A, Geschwind MD, Belfor N, Gorno-Tempini ML, Schauer GF, Miller BL, Weiner MW, Rosen HJ. Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy. Arch Neurol. 2006 Jan; 63(1):81-6. PMID: 16401739.
      View in: PubMed
    97. Goldman JS, Farmer JM, Wood EM, Johnson JK, Boxer A, Neuhaus J, Lomen-Hoerth C, Wilhelmsen KC, Lee VM, Grossman M, Miller BL. Comparison of family histories in FTLD subtypes and related tauopathies. Neurology. 2005 Dec 13; 65(11):1817-9. PMID: 16344531.
      View in: PubMed
    98. Belfor N, Amici S, Boxer A, Kramer JH, Gorno-Tempini ML, Rosen HJ, Miller BL. Clinical and neuropsychological features of corticobasal degeneration. Mech Ageing Dev. 2006 Feb; 127(2):203-7. PMID: 16310834.
      View in: PubMed
    99. Boxer A, Miller BL. Clinical features of frontotemporal dementia. Alzheimer Dis Assoc Disord. 2005 Oct-Dec; 19 Suppl 1:S3-6. PMID: 16317256.
      View in: PubMed
    100. Boxer A, Kramer JH, Johnston K, Goldman J, Finley R, Miller BL. Executive dysfunction in hyperhomocystinemia responds to homocysteine-lowering treatment. Neurology. 2005 Apr 26; 64(8):1431-4. PMID: 15851736.
      View in: PubMed
    101. Boxer A, Kramer JH, Du AT, Schuff N, Weiner MW, Miller BL, Rosen HJ. Focal right inferotemporal atrophy in AD with disproportionate visual constructive impairment. Neurology. 2003 Dec 09; 61(11):1485-91. PMID: 14663029; PMCID: PMC2744649.
    102. Boxer A, Rankin KP, Miller BL, Schuff N, Weiner M, Gorno-Tempini ML, Rosen HJ. Cinguloparietal atrophy distinguishes Alzheimer disease from semantic dementia. Arch Neurol. 2003 Jul; 60(7):949-56. PMID: 12873851.
      View in: PubMed
    Adam's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _
    Back to TOP